New drug combo aims to shrink liver tumors before surgeons operate

NCT ID NCT05908786

Summary

This study tested whether giving patients with operable liver cancer a short course of immune-boosting drug combinations before surgery could help shrink their tumors. The goal was to see if this 'neoadjuvant' approach could lead to better surgical outcomes and lower the chance of the cancer coming back. The trial involved 62 participants and was designed to test different drug combinations as they became available.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Assistance Publique-Hopitaux de Paris

    Villejuif, 94800, France

  • Auckland District Health Board (ADHB)

    Auckland, 1023, New Zealand

  • Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Main Campus

    Detroit, Michigan, 48201-2013, United States

  • CHA Bundang Medical Center

    Seongnam-si, Gyeonggi-do, 463-712, South Korea

  • Centre Eugene Marquis (CEM)

    Rennes, 35042, France

  • Centre Georges Francois Leclerc (CGFL)

    Dijon, 21079, France

  • Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital

    Tainan, 83301, Taiwan

  • Clínica Universidad de Navarra

    Pamplona, Navarre, 31620, Spain

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Department of Internal Medicine III AKH and Medical University of Vienna

    Vienna, 1180, Austria

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20007, United States

  • Gustave Roussy

    Villejuif, 94800, France

  • Hospital Clinic de Barcelona (Hospital Clinic i Provincial)

    Barcelona, 8036, Spain

  • Hospital Universitario Fundacion Jimenez Diaz.

    Madrid, 28040, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Imperial College London - Imperial Centre for Translational and Experimental Medicine (ICTEM)

    London, United Kingdom

  • Klinikum Klagenfurt am Wörthersee

    Klagenfurt, 9020, Austria

  • National Cheng Kung University Hospital

    Tainan, 70457, Taiwan

  • National Taiwan University Hospital (NTUH) - Cancer Research Center

    Zhongzheng Dist., 10051, Taiwan

  • Severance Hospital, Yonsei University Health System

    Seoul, 003-722, South Korea

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 112, Taiwan

  • UT Southwestern Medical Center

    Dallas, Texas, 75390-8813, United States

  • Universitaets Klinikum Frankfurt - Zentrum der Inneren Medizin

    Frankfurt, 60596, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, 55131, Germany

  • University Essen

    Essen, 45147, Germany

  • University of California Los Angeles (UCLA) - Cancer Care - Santa Monica

    Santa Monica, California, 90404-2023, United States

  • University of Southern California (USC)

    Los Angeles, California, 90033, United States

  • Wiener Gesundheitsverbund, Klinik Favoriten

    Vienna, 1100, Austria

Conditions

Explore the condition pages connected to this study.